EphA2 blockage ALW-II-41-27 alleviates atherosclerosis by remodeling gut microbiota to regulate bile acid metabolism DOI Creative Commons
Cong Lu, Dan Liu, Qiao Wu

et al.

npj Biofilms and Microbiomes, Journal Year: 2024, Volume and Issue: 10(1)

Published: Oct. 19, 2024

Coronary artery disease (CAD), a critical condition resulting from systemic inflammation, metabolic dysfunction, and gut microbiota dysbiosis, poses global public health challenge. ALW-II-41-27, specific inhibitor of the EphA2 receptor, has shown anti-inflammatory prosperities. However, impact ALW-II-41-27 on atherosclerosis not been elucidated. This study aimed to examine roles pharmacologically inhibiting underlying mechanism in ameliorating atherosclerosis. was administered apoE−/− mice fed high-fat diet via intraperitoneal injection. We first discovered that led significant reduction atherosclerotic plaques, evidenced by reduced lipid macrophage accumulation, alongside an increase collagen smooth muscle cell content. also significantly lowered plasma hepatic cholesterol levels, as well colonic inflammation. Furthermore, analyzed metagenomics metabolites untargeted metabolomics. ALW-II-41-27-treated enriched Enterococcus, Akkermansia, Eggerthella Lactobaccilus, accompanied enhanced secondary bile acids production. To explore causal link between ALW-II-41-27-associated atherosclerosis, fecal transplantation employed. Mice received mouse feces exhibited attenuated plaque. In clinical, lower DCA HDCA levels were determined CAD patients using quantitative metabolomics negative correlation with higher monocytes expression. Our findings underscore potential novel therapeutic agent for highlighting its capacity modulate composition acid metabolism, thereby offering promising avenue CAD.

Language: Английский

A microbiota pattern associated with cardiovascular events in secondary prevention: the CORDIOPREV study DOI
Javier Arenas‐Montes, Juan F. Alcalá‐Díaz, Helena García-Fernández

et al.

European Heart Journal, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Abstract Background and Aims Preventing new cardiovascular events in patients with established disease (CVD) is a daunting task for clinicians. Intestinal microbiota may help identify at risk, thus improving the strategies of secondary prevention. The aim this study was to evaluate baseline differences between gut from coronary heart (CHD) suffering major adverse (MACEs) following 7 years, compared CHD who did not undergo MACE period, build score associated risk MACE. Methods Within framework CORDIOPREV study, clinical trial that involved 1002 CHD, intestinal examined available faecal samples (n = 679, 132 MACE), through 16S metagenomics on Illumina MiSeq Quiime2 software. Lipopolysaccharide (LPS) measured using limulus amoebocyte lysate test. Results Random survival forest identified 10 bacterial taxa higher predictive power incidence. Receiver operating characteristic curves yielded an area under curve 65.2% (59.1%–71.3%) training set 68.6% (59.3%–77.9%) validation set. incidence hazard ratio 2.01 (95% confidence interval 1.37–3.22). analysis showed greater LPS post-prandial fold change group (P .005). Conclusions These results reinforce relationship CVD suggest profile patients, addition endotoxaemia.

Language: Английский

Citations

1
Gut Microbiota and Metabolic Alterations Associated with Heart Failure and Coronary Artery Disease DOI Open Access
A. A. Yafarova, Elena V. Dementeva, Olga A. Zlobovskaya

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11295 - 11295

Published: Oct. 20, 2024

This study investigates the role of gut microbiota in cardiovascular diseases, with an additional focus on pro-atherogenic metabolites. We use advanced network analysis and machine learning techniques to identify key microbial features linked coronary artery disease (CAD) heart failure reduced ejection fraction (HFrEF). cross-sectional included 189 participants divided into three groups: (

Language: Английский

Citations

3
Chronic inflammation and vascular cell plasticity in atherosclerosis DOI
Alexander Y. Lin, Joseph M. Miano, Edward A. Fisher

et al.

Nature Cardiovascular Research, Journal Year: 2024, Volume and Issue: 3(12), P. 1408 - 1423

Published: Dec. 9, 2024

Language: Английский

Citations

3
Artificial Intelligence-Based Target for Personalized Interventions of Atherosclerosis from Gut Microbiota Signature DOI Creative Commons
Suravi Majumder, Koushik Sen, Rabimba Karanjai

et al.

SynBio, Journal Year: 2025, Volume and Issue: 3(1), P. 2 - 2

Published: Jan. 9, 2025

Atherosclerosis remains a major driver for cardiovascular disease (CVD), despite advancements in traditional risk factor management therapies. Recent evidence emphasizes the crucial role of gut microbiome progression atherosclerosis and plaque rupture, highlighting promising therapeutic avenue. This review focuses on intertwined relationship between microbiome, its metabolites, CVD, also potential probiotics prebiotics. Given diverse unique microbiota signatures among individuals, one-size-fits-all approach is unlikely to be effective. Personalized treatment strategies are therefore necessary. Here, we discussed how Artificial Intelligence (AI) can leveraged analyze individual profiles from sequencing, predict response, optimize based patients, which would significantly improve outcomes patients.

Language: Английский

Citations

0
Traditional Chinese medicine Yiqi Huoxue Huatan recipe inhibits atherosclerosis by regulating intestinal flora and its associated metabolites DOI Creative Commons
Hongtao Huang,

Wei Lv,

Hanjun Zhao

et al.

Pharmacological Research - Modern Chinese Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 100593 - 100593

Published: Feb. 1, 2025

Language: Английский

Citations

0
Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches DOI Creative Commons
Mohamed Zaiou, Olivier Joubert

Biomolecules, Journal Year: 2025, Volume and Issue: 15(5), P. 669 - 669

Published: May 5, 2025

Nonalcoholic fatty liver disease (NAFLD) is a growing global health concern, impacting approximately 32.4% of the worldwide population. As linked to metabolic dysfunction, NAFLD continues rise alongside increases in obesity, type 2 diabetes mellitus (T2DM), and syndrome. There considerable evidence indicating that disproportionately affects racial, ethnic, minority groups, although exact reasons for these disparities remain elusive. Contributing factors this may include socioeconomic status, cultural influences, stress, genetic factors, lifestyle choices. Emerging suggests causal could influence epigenetic mechanisms, particularly DNA methylation histone modifications, as well composition diversity gut microbiota. Nevertheless, there scarcity research comprehensively examines interplay between changes microbiome variations relation across different racial ethnic populations globally. This paper intends (i) explore connections NAFLD, disparities, microbiota composition, alterations, while reviewing pertinent studies illustrate how contribute inequities among various groups impacted by disease; (ii) potential therapeutic targets biomarkers advance management NAFLD; (iii) provide insights enhance our understanding mechanisms associated with disease, thereby promoting further field. Advancements area are anticipated susceptibilities at-risk new options its complications.

Language: Английский

Citations

0
Sotagliflozin attenuates cardiac dysfunction and depression-like behaviors in mice with myocardial infarction through the gut-heart-brain axis DOI Creative Commons

Lei Liao,

Lu Zhang,

Chengying Yang

et al.

Neurobiology of Disease, Journal Year: 2024, Volume and Issue: 199, P. 106598 - 106598

Published: July 11, 2024

Myocardial infarction (MI) and depression are leading causes of mortality morbidity globally, these conditions increasing recognized as being fundamentally interconnected. The recently gut-heart-brain axis offers insights into following MI, but effective treatments for this comorbidity remain lacking. To address medical need, we employed an animal model MI to investigate the potential repurposing sotagliflozin (SOTA), approved sodium-glucose cotransporter 1 2 (SGLT1/2) inhibitor diabetes, managing identifying SOTA-associated microbial mechanisms. SOTA treatment improved cardiac dysfunction alleviated depression-like behaviors induced by accompanied alterations in gut microbiota composition, such changes Prevotellaceae NK3B31 group, Alloprevotella, UCG-001. Moreover, fecal transplantation (FMT) using samples from SOTA-treated mice demonstrated that contributed beneficial effects on mice. Intriguingly, FMT-based intervention concordance analysis before after FMT suggested UCG-001 were associated with SOTA. Furthermore, functional prediction correlation support significance dynamic communities. In conclusion, findings suggest could serve a drug ameliorate depressive symptoms patients via through axis.

Language: Английский

Citations

3
Akkermansia muciniphila - impact on the cardiovascular risk, the intestine inflammation and obesity DOI Creative Commons

Krzysztof Gofron,

Adam Berezowski,

M. Stolyhwo Gofron

et al.

Acta Biochimica Polonica, Journal Year: 2024, Volume and Issue: 71

Published: Nov. 14, 2024

Contemporary scientific discussions are increasingly focusing on Akkermansia muciniphila due to its complex influence intestinal physiology. This article provides a comprehensive analysis of the various effects has inflammation, while also exploring potential associations with obesity and cardiovascular diseases. A systematic literature search was conducted using PubMed, Google Scholar, ResearchGate following keywords: , obesity, risk, inflammatory bowel The aim our mini-review examine impact bacteria intestines, system, relationship obesity. Through detailed review current literature, seeks elucidate interactions within human body, highlighting contributions health improvement medical interventions. Research indicates that positively correlates maintaining health, modulating aiding in weight management. However, number studies available is small, require further research.

Language: Английский

Citations

3
Epidemiological Study on the Interaction between the PNPLA3 (rs738409) and Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease DOI Open Access
Satoshi Sato, Chikara Iino,

Takafumi Sasada

et al.

Genes, Journal Year: 2024, Volume and Issue: 15(9), P. 1172 - 1172

Published: Sept. 6, 2024

Many factors are associated with the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD); however, genetics gut microbiota representative factors. Recent studies have highlighted link between host genes microbiota. Although there been many on separate effects single nucleotide polymorphisms (SNPs) bacteria MASLD, few epidemiological examined how SNPs interact in MASLD. This study aimed to investigate association PNPLA3 rs738409, a MASLD-related SNP, MASLD using cross-sectional general population. The 526 participants (318 normal 208 groups) were grouped into rs738409 CC, CG, GG genotypes, differences investigated each group. CC CG genotypes decreased Blautia Ruminococcaceae They negatively correlated controlled attenuation parameter levels, body mass index, serum blood glucose, triglycerides. In contrast, was no groups genotype finding implies that dietary interventions probiotics may be more effective preventing treating individuals genotypes. their efficacy limited those genotype.

Language: Английский

Citations

1
Sex Differences in Cardiovascular Diseases: Exploring the Role of Microbiota and Immunity DOI Creative Commons
Laura Franza, Mario Caldarelli, Emanuele Rocco Villani

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1645 - 1645

Published: July 24, 2024

Cardiovascular diseases (CVDs) are the most common cause of mortality and morbidity in Western countries, thus representing a global health concern. CVDs show different patterns terms prevalence presentation men women. The role sex hormones has been extensively implicated these sex-specific differences, due to presence menstrual cycle menopause Moreover, gut microbiota (GM) cardiovascular health, considering growing evidence that it is involved determining development specific diseases. In particular, gut-derived metabolites have linked kidney disorders, which can turn promote progression CVDs. Considering differences composition GM between women, possible act as mediator regard disparities This narrative review aims comprehensively interplay sex, GM, CVDs, discussing potential mechanisms therapeutic options.

Language: Английский

Citations

1